On Nov. 2, 2022, Hologic announced that it had been awarded a $19 million contract from the Biomedical Advanced Research and Development Authority (BARDA) to support research and development efforts. This funding will help to bring Hologicﾒs Panther Fusionﾮ SARS-CoV-2/Flu A/B/RSV assay and Aptimaﾮ SARS-CoV-2 assay in line with the U.S. Food and Drug Administrationﾒs in vitro diagnostic standards.